# Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

> **NCT00196937** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 667 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Cervarix

## Key facts

- **NCT ID:** NCT00196937
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-07
- **Primary completion:** 2005-12-15
- **Final completion:** 2005-12-15
- **Target enrollment:** 667 (ACTUAL)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00196937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00196937, "Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00196937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*